Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 3
Submit an article Journal homepage
1,962
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis

Wei Xua Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing, ChinaCorrespondence[email protected]
View further author information
,
Shenmiao Yangb Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, ChinaView further author information
,
Keshu Zhouc Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaView further author information
,
Ling Pand West China Hospital of Sichuan University, Chengdu, ChinaView further author information
,
Zengjun Lie Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, ChinaView further author information
,
Sujun Gaof The First Hospital of Jilin University, Changchun, ChinaView further author information
,
Daobin Zhoug Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaView further author information
,
Jianda Huh Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, ChinaView further author information
,
Ru Fengi Nanfang Hospital of Southern Medical University, Guangzhou, ChinaView further author information
,
Haiwen Huangj The First Hospital of Soochow University, Suzhou, ChinaView further author information
,
Tingyu Wange Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, ChinaView further author information
,
Dengju Lik Tongji Hospital, Tongji Medical College, Wuhan, ChinaView further author information
,
Meng Jil BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
,
Haiyi Guol BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
,
Xia Zhaol BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAORCID Iconhttps://orcid.org/0000-0002-2751-7160View further author information
ORCID Icon,
Binghao Wul BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
,
Yiling Yul BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
,
Yu Wangl BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
,
Jane Huangl BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
,
William Novotnyl BeiGene (Beijing) Co., Ltd., Beijing, China;m BeiGene (Shanghai) Co., Ltd., Shanghai, China;n BeiGene USA, Inc., San Mateo, CA, USAView further author information
&
Jianyong Lia Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 712-716 | Received 24 Jun 2022, Accepted 29 Dec 2022, Published online: 17 Feb 2023

References

  • Noy A, de Vos S, Thieblemont C, et al. Targeting bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
  • Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):48.
  • Hallek M, Cheson BD, Catovsky D, International Workshop on Chronic Lymphocytic Leukemia, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer Institute-Working group 1996 guidelines. Blood. 2008;111(12):5446–5456.
  • Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735–743.
  • Sedlarikova L, Petrackova A, Papajik T, et al. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020;10:894.
  • Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
  • Byrd JC, Brown JR, O'Brien S, RESONATE Investigators, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332.
  • Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs. ofatumumab. Blood. 2019;133(19):2031–2042.
  • Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204–1213.
  • Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–1817.
  • Barrientos JC, Burger JA, Byrd JC, et al. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019;60(4):1000–1005.
  • Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs. ibrutinib in symptomatic waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–2050.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.